Image Source: AsiaOne
Pivotal Preclinical Oncology Platform Expands to Include New Patient-Derived Organoid Models~ HUB patient-derived organoids (PDO) added to CrownBio’s unique platform designed to disrupt traditional drug discovery workflows ~GlobeNewswireMay 26, 2020SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB) patient-derived organoids (PDO). This marks a significant milestone in the development of CrownBio’s innovative organoid platform and the first, large-scale commercial availability of HUB PDO for oncology drug discovery services.
Source: AsiaOne